SWK Holdings Corp

NASDAQ SWKH

Download Data

SWK Holdings Corp EBIT to Fixed Assets Ratio 3 year CAGR for the quarter ending March 31, 2024: 34.51%

SWK Holdings Corp EBIT to Fixed Assets Ratio 3 year CAGR is 34.51% for the quarter ending March 31, 2024. The EBIT to Fixed Assets Ratio measures a company's operating earnings (EBIT) generated per dollar of fixed assets (property, plant, and equipment). It indicates how efficiently a company utilizes its fixed assets to generate earnings. A higher ratio suggests better earnings generation from fixed assets, indicating improved operational efficiency and potentially higher profitability. CAGR, or the Compound Annual Growth Rate, quantifies the mean annual growth rate of an investment or financial metric over a specified time span, considering the influence of compounding. It is instrumental in determining the true annualized return on an investment.
  • SWK Holdings Corp EBIT to Fixed Assets Ratio for the quarter ending March 31, 2023 was 0.95, a 7.19% change year over year.
  • SWK Holdings Corp EBIT to Fixed Assets Ratio for the quarter ending March 31, 2022 was 0.88, a 47.62% change year over year.
  • SWK Holdings Corp EBIT to Fixed Assets Ratio for the quarter ending March 31, 2021 was 0.60, a 297.56% change year over year.
  • SWK Holdings Corp EBIT to Fixed Assets Ratio for the quarter ending March 31, 2020 was -0.30.
NASDAQ: SWKH

SWK Holdings Corp

CEO Mr. Jody Staggs
IPO Date Sept. 22, 1999
Location United States
Headquarters 14755 Preston Road, Dallas, TX, United States, 75254
Employees 22
Sector Financial Services
Industry Asset management
Description

SWK Holdings Corporation, offers specialty finance and asset management services in the United States. It operates in two segments, Finance Receivables and Pharmaceutical Development. The Finance Receivables segment provides customized financing solutions to a range of life science companies, including companies in the biotechnology, medical device, medical diagnostics and related tools, animal health, and pharmaceutical industries, as well as institutions and inventors. This segment also offers non-discretionary investment advisory services to institutional clients in separately managed accounts to invest in life science finance. The Pharmaceutical Development segment provides customers pharmaceutical development, formulation, and manufacturing services, as well as formulation solutions built around its proprietary oral drug delivery technologies, the Peptelligence platform. It also offers intellectual property licensing business. The company was formerly known as Kana Software, Inc. and changed its name to SWK Holdings Corporation in December 2009. SWK Holdings Corporation was incorporated in 1996 and is headquartered in Dallas, Texas.

StockViz Staff

September 20, 2024

Any question? Send us an email